https://us.pharmaessentia.com/pharmaessentia-presents-at-the-j-p-morgan-43rd-annual-healthcare-conference/ 2025-11-04T21:02:08+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/PEC_JPM_1.png https://us.pharmaessentia.com/wp-content/uploads/2021/06/FDA-File-Acceptance-Release-June-3-2021.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/us-fda-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/05/PEC-Resubmits-for-FDA-Approval-14-May-2021.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/04/Chairperson-Japan-April-2021.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/03/US-Regulatory-Update-March-2021.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/01/ET-Trial-Start-Release-7-Jan.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/01/JPM-Presentation-Release-5-Jan.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2020/12/Pharma-Essentia-ASH-Data-Release_12.7-Final.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2020/11/ASH-Curtain-Raiser-Release_4-Nov.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2020/10/Dr.-Urbanski-Press-Release_Final.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2020/08/PharmaEssentia-Aug-3.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/time-magazine-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2020/09/Filing-Acceptance-Release-Final-Updated-5-Jun.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/us-fda-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/09/PEC-Welcomes-Roddy-McIlwain-27-Sept.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/10/Welcoming-Sulin-Shah_5-Oct.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/10/S-Korea-Approval-14-Oct.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2021/10/PEC-at-ASH-2021-21-Oct.pdf#new_tab 2025-11-04T21:02:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/ASH.png https://us.pharmaessentia.com/475-final-results-from-proud-pv-a-randomized-controlled-phase-3-trial-comparing-ropeginterferon-alfa-2b-to-hydroxyurea-in-polycythemia-vera-patients/ 2025-11-04T21:02:20+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/forbes-asia-pharmaessentia-on-the-road-to-product-launch-chmp-recommended-granting-marketing-authorization-for-ropeginterferon/ 2025-11-04T21:02:20+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/forbes-asia-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2025/10/forbes-custom-1.jpg https://us.pharmaessentia.com/wp-content/uploads/2025/10/forbes-custom-2.jpg https://us.pharmaessentia.com/pharmaessentia-and-aop-orphan-receive-positive-chmp-opinion-for-besremi-ropeginterferon-alfa-2b-for-treatment-of-polycythemia-vera-pv-in-eu/ 2025-11-04T21:02:20+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/cision-thumb.png https://us.pharmaessentia.com/pharmaessentia-updates-progress-of-ropeginterferon-alfa-2b-clinical-program/ 2025-11-04T21:02:20+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/pharma-essentia-thumb.png https://us.pharmaessentia.com/milestone-magazine-a-healthy-business-ko-chung-lin/ 2025-11-04T21:02:20+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/milestone-magazine-thumb.png https://us.pharmaessentia.com/wp-content/uploads/2025/10/milestone-1.png https://us.pharmaessentia.com/wp-content/uploads/2025/10/milestone-2.jpg https://us.pharmaessentia.com/u-s-fda-approves-besremir-ropeginterferon-alfa-2b-njft-as-the-only-interferon-for-adults-with-polycythemia-vera/ 2025-12-24T13:24:00+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Logo-1-scaled.png https://us.pharmaessentia.com/pharmaessentias-besremi-ropeginterferon-alfa-2b-njft-now-available-for-the-treatment-of-people-with-pv-in-the-united-states/ 2025-12-24T13:43:36+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Logo-1-scaled.png https://us.pharmaessentia.com/where-it-all-began/ 2026-02-09T18:38:50+00:00 https://us.pharmaessentia.com/pharmaessentia-expands-u-s-leadership-with-anjana-pursnani-head-of-people-and-jason-mitch-head-of-market-access/ 2026-02-09T18:41:09+00:00 https://us.pharmaessentia.com/nccn-clinical-practice-guidelines-in-oncology-update-recommends-besremir-ropeginterferon-alfa-2b-njft-for-the-treatment-of-polycythemia-vera/ 2026-02-09T18:45:28+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Guidelines.png https://us.pharmaessentia.com/pharmaessentia-japan-files-marketing-authorization-application-for-ropeginterferon-alfa-2b-for-the-treatment-of-polycythemia-vera/ 2026-02-09T18:46:14+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-appointment-of-meredith-manning-to-president-of-the-americas/ 2026-02-09T18:47:24+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/MM-for-web-1-scaled.png https://us.pharmaessentia.com/new-data-on-ropeginterferon-alfa-2b-to-be-featured-at-eha2022/ 2026-02-09T18:48:40+00:00 https://us.pharmaessentia.com/pharmaessentia-honored-at-the-national-organization-of-rare-disorders-nordr-2022-rare-impact-awards-for-the-introduction-of-besremir-ropeginterferon-alfa-2b-for-polycythemia-vera/ 2026-02-09T18:51:11+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/NORD2-scaled.png https://us.pharmaessentia.com/pharmaessentia-appoints-dr-lih-ling-lin-as-chief-scientific-officer/ 2026-02-09T18:51:52+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Pharma.Besremi.22.006977-001-Dr.-Lin-Appointment_w01_TWI-1.jpg https://us.pharmaessentia.com/review-of-surpass-et-trial-evaluating-ropeginterferon-alfa-2b-njft-for-essential-thrombocythemia-et-published-in-future-oncology/ 2026-02-09T18:52:52+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Surpass-for-web.jpg https://us.pharmaessentia.com/pharmaessentia-defines-a-growth-oriented-discovery-and-development-strategy-with-newly-appointed-cso-dr-lih-ling-lin-at-the-helm/ 2026-02-09T18:53:46+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Lih-Ling-1.jpg https://us.pharmaessentia.com/pharmaessentia-usa-expands-leadership-with-executive-hires-in-marketing-medical-affairs-and-communications-and-advocacy/ 2026-02-09T18:54:16+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/New-leaders-Oct-2022.png https://us.pharmaessentia.com/pharmaessentia-corporation-announces-closing-of-follow-on-public-offering-generating-more-than-200m-usd-to-support-growth-ambitions/ 2026-02-09T18:54:52+00:00 https://us.pharmaessentia.com/presentations-on-ropeginterferon-alfa-2b-during-ash-annual-meeting-highlight-momentum-in-the-care-of-polycythemia-vera-pv/ 2026-02-09T18:55:47+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/ASH.png https://us.pharmaessentia.com/pharmaessentia-to-host-investor-day-in-new-york-city-on-november-30-2022/ 2026-02-09T18:56:25+00:00 https://us.pharmaessentia.com/new-ropeginterferon-alfa-2b-data-show-importance-of-proactive-care-earlier-in-the-polycythemia-vera-patient-journey/ 2026-02-09T18:57:59+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/ASH-1-scaled.png https://us.pharmaessentia.com/pharmaessentia-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2026-02-09T18:58:43+00:00 https://us.pharmaessentia.com/pharmaessentia-establishes-a-new-research-and-development-facility-in-the-boston-area/ 2026-02-09T18:59:14+00:00 https://us.pharmaessentia.com/clinical-review-of-ropeginterferon-alfa-2b-suggests-amended-dosing-schedule-may-support-improved-clinical-outcomes-in-polycythemia-vera/ 2026-02-09T19:00:42+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Frontiers-image-scaled.png https://us.pharmaessentia.com/pharmaessentia-initiates-phase-2b-trial-of-ropeginterferon-alfa-2b-njft-for-essential-thrombocythemia-et-in-north-america/ 2026-02-09T19:01:44+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/EXCEED-ET-Study-Logo.png https://us.pharmaessentia.com/pharmaessentia-corporation-announces-closing-of-global-depositary-receipt-offering-generating-us462-7m-to-support-growth-plans-and-pipeline-development/ 2026-02-09T19:02:52+00:00 https://us.pharmaessentia.com/pharmaessentia-initiates-phase-3b-trial-of-ropeginterferon-alfa-2b-njft-investigating-new-dosing-regimen-for-patients-with-polycythemia-vera-pv/ 2026-02-09T19:04:09+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/ECLIPSE-PV-SIZED-FOR-PR-UPLOAD-1.png https://us.pharmaessentia.com/nccn-clinical-practice-guidelines-in-oncology-updated-to-recommend-besremi-ropeginterferon-alfa-2b-njft-as-a-preferred-intervention-for-polycythemia-vera/ 2026-02-09T19:06:07+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Guidelines.png https://us.pharmaessentia.com/pharmaessentia-selects-pint-pharma-as-commercial-partner-for-besremi-ropeginterferon-alfa-2b-njft-in-latin-america/ 2026-02-09T19:07:19+00:00 https://us.pharmaessentia.com/new-ropeginterferon-alfa-2b-data-suggest-alternate-dosing-schedule-may-achieve-greater-and-quicker-complete-hematologic-and-molecular-responses-in-polycythemia-vera/ 2026-02-09T19:08:03+00:00 https://us.pharmaessentia.com/new-study-demonstrates-ropeginterferon-alfa-2b-njft-is-a-cost-effective-treatment-option-for-a-broad-range-of-patients-with-polycythemia-vera/ 2026-02-09T19:09:49+00:00 https://us.pharmaessentia.com/pharmaessentia-and-mpn-advocacy-education-international-launch-new-educational-initiative-to-empower-people-living-with-polycythemia-vera-pv/ 2026-02-09T19:10:35+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/PVME-LOGO.png https://us.pharmaessentia.com/pharmaessentia-included-in-ftse-russell-indices/ 2026-02-09T19:11:06+00:00 https://us.pharmaessentia.com/pharmaessentia-enters-into-exclusive-global-license-agreement-with-wuxi-biologics-for-a-myeloid-immune-checkpoint-antibody-candidate/ 2026-02-09T19:11:31+00:00 https://us.pharmaessentia.com/presentations-at-mpn-congress-and-ash-annual-meeting-reinforce-clinical-role-of-ropeginterferon-alfa-2b-njft/ 2026-02-09T19:12:37+00:00 https://us.pharmaessentia.com/clinical-review-of-pegylated-interferons-suggests-formulation-and-mechanism-of-action-may-improve-outcomes-for-mpn-patients-2/ 2026-02-09T19:14:26+00:00 https://us.pharmaessentia.com/pharmaessentias-besremi-ropeginterferon-alfa-2b-njft-now-recommended-as-a-preferred-first-line-cytoreductive-therapy-for-polycythemia-vera-in-updated-nccn-clinical-practice-guidelines-in-oncology/ 2026-02-09T19:15:55+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Guidelines.png https://us.pharmaessentia.com/analyses-find-patients-with-polycythemia-vera-pv-treated-with-besremi-ropeginterferon-alfa-2b-had-increased-probability-of-achieving-complete-hematologic-response/ 2026-02-09T19:17:32+00:00 https://us.pharmaessentia.com/pharmaessentia-appoints-robert-geller-m-d-as-head-of-medical/ 2026-02-09T19:18:34+00:00 https://us.pharmaessentia.com/besremi-ropeginterferon-alfa-2b-shows-greatest-benefit-among-cytoreductive-therapies-in-lowering-symptomatic-burden-of-polycythemia-vera-pv-real-world-analysis-published-at-asco/ 2026-02-09T19:20:53+00:00 https://us.pharmaessentia.com/pharmaessentia-appoints-fred-paster-as-head-of-commercial/ 2026-02-09T19:21:23+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Fred-Paster-PEC-Website.jpg https://us.pharmaessentia.com/pharmaessentia-completes-patient-enrollment-for-phase-2b-exceed-et-trial-in-essential-thrombocythemia-and-phase-3b-eclipse-pv-trial-in-polycythemia-vera/ 2026-02-09T19:22:46+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Untitled-800-x-418-px.jpg https://us.pharmaessentia.com/pharmaessentia-promotes-robert-b-geller-m-d-to-general-manager/ 2026-02-09T19:24:13+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Robert-Geller-PEC-Website.png https://us.pharmaessentia.com/pharmaessentia-appoints-beth-a-krewson-as-head-of-legal/ 2026-02-09T19:24:48+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Beth-Krewson-Press-Release-800-x-418-px.jpg https://us.pharmaessentia.com/pharmaessentia-announces-licensing-agreement-with-forus-therapeutics-to-commercialize-besremi-ropeginterferon-alfa-2b-njft-in-canada/ 2026-02-09T19:26:19+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Canada-Deal-PEC-800-x-418-px.png https://us.pharmaessentia.com/pharmaessentia-to-participate-in-upcoming-investor-conferences-2/ 2026-02-09T19:26:42+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-nine-data-presentations-at-ash-annual-meeting/ 2026-02-09T19:28:09+00:00 https://us.pharmaessentia.com/pharmaessentia-appoints-joseph-r-horvat-as-global-chief-commercial-officer/ 2026-02-09T19:28:45+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/Joe-Horvat-Website-Image.jpg https://us.pharmaessentia.com/pharmaessentia-to-present-at-the-annual-j-p-morgan-healthcare-conference-on-january-16-2025/ 2026-02-09T19:29:13+00:00 https://us.pharmaessentia.com/pharmaessentia-reaffirms-its-commitment-to-robust-and-reliable-access-to-interferon-therapies-amid-global-supply-challenges/ 2026-02-09T19:30:33+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-evaluating-ropeginterferon-alfa-2b-njft-p1101-for-essential-thrombocythemia/ 2026-02-09T19:31:19+00:00 https://us.pharmaessentia.com/pharmaessentia-highlights-availability-of-besremi-ropeginterferon-alfa-2b-njft-for-patients-affected-by-pegasys-peginterferon-alfa-2a-drug-shortage/ 2026-02-09T19:33:34+00:00 https://us.pharmaessentia.com/pharmaessentia-to-present-phase-3-surpass-et-data-in-oral-session-at-2025-asco-annual-meeting/ 2026-02-09T19:34:24+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-presentations-at-eha-2025-highlighting-clinical-advances-in-myeloproliferative-neoplasms/ 2026-02-09T19:35:11+00:00 https://us.pharmaessentia.com/pharmaessentia-to-participate-at-morgan-stanley-23rd-annual-global-healthcare-conference/ 2026-02-09T19:35:40+00:00 https://us.pharmaessentia.com/pharmaessentia-usa-announces-appointment-of-dr-barry-flannelly-as-independent-director/ 2026-02-09T19:35:57+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/11/1675645489049.webp https://us.pharmaessentia.com/pharmaessentia-announces-publication-of-phase-3-surpass-et-results-in-the-lancet-haematology/ 2026-02-09T19:37:57+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-presentation-at-j-p-morgan-healthcare-conference-and-strategic-priorities-for-2026/ 2026-02-09T19:39:11+00:00 https://us.pharmaessentia.com/pharmaessentia-usa-announces-appointment-of-jeffrey-williams-as-independent-director/ 2026-02-09T19:40:17+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-positive-topline-phase-2b-data-from-exceed-et-study-evaluating-ropeginterferon-alfa-2b-njft-for-essential-thrombocythemia/ 2026-02-09T19:42:15+00:00 https://us.pharmaessentia.com/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia-et/ 2026-02-09T19:43:52+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-updated-nccn-clinical-practice-guidelines-include-ropeginterferon-alfa-2b-njft-besremi-for-treatment-of-essential-thrombocythemia-et/ 2026-02-09T19:45:54+00:00 https://us.pharmaessentia.com/aop-orphan-announces-three-year-results-on-ropeginterferon-alfa-2b-in-polycythemia-vera-at-the-american-society-of-hematology-ash-annual-meeting-2018/ 2026-02-28T19:17:36+00:00 https://us.pharmaessentia.com/wp-content/uploads/2025/10/aop-orphan-thumb.png https://us.pharmaessentia.com/pharmaessentia-announces-plans-to-establish-new-us-manufacturing-facility-in-puerto-rico-to-support-global-growth-of-besremi/ 2026-02-28T19:17:58+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-japan-approval-of-high-dose-dosing-regimen-for-besremi/ 2026-03-02T15:14:44+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-presentations-at-ash-2025/ 2026-03-13T16:58:17+00:00 https://us.pharmaessentia.com/pharmaessentia-signs-investment-agreement-for-new-manufacturing-facility-in-puerto-rico/ 2026-04-14T19:53:36+00:00 https://us.pharmaessentia.com/taiwans-representative-to-the-united-states-alexander-tah-ray-yui-visits-pharmaessentias-puerto-rico-facility-alongside-puerto-rico-officials/ 2026-04-27T18:24:29+00:00 https://us.pharmaessentia.com/wp-content/uploads/2026/04/WhatsApp-Image-2026-04-22-at-2.43.27-PM-2.jpeg https://us.pharmaessentia.com/pharmaessentia-to-present-new-clinical-data-supporting-the-use-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-at-asco-and-eha-2026/ 2026-05-22T18:28:52+00:00 https://us.pharmaessentia.com/pharmaessentia-appoints-eric-vogel-as-u-s-head-of-commercialization-ahead-of-potential-launch-of-besremi-in-essential-thrombocythemia/ 2026-05-28T00:23:23+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-taiwan-approval-of-besremi-for-essential-thrombocythemia-marking-first-global-approval-in-et/ 2026-06-10T14:34:34+00:00 https://us.pharmaessentia.com/pharmaessentia-expands-north-american-commercial-footprint-with-acquisition-of-canadian-partner-forus-therapeutics/ 2026-06-11T14:30:58+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-fda-approval-and-u-s-launch-of-besremi-pen-ropeginterferon-alfa-2b-njft-for-polycythemia-vera/ 2026-06-26T13:23:55+00:00 https://us.pharmaessentia.com/pharmaessentia-announces-health-canada-approval-of-besremi-ropeginterferon-alfa-2b-for-polycythemia-vera-pv/ 2026-07-06T12:12:16+00:00